EGElizabeth M. Gore

Elizabeth M. Gore

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Elizabeth M. Gore has a total of 114 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A Multimodal Artificial Intelligence Model to Guide Use of Whole-Pelvic Radiation Therapy in Patients with Localized Prostate Cancer: Exploratory Analysis of RTOG 9413

    by Mutlay Sayan, Huei-Chung Huang, Erin L. Stewart, Timothy N. Showalter, Adam P. Dicker, George Daniel Grass, Elizabeth M. Gore, Andrew Michael McDonald, J. Daniel Pennington, Mark A. Hallman, et al.

    Background/Objectives: This study explored whether a multimodal artificial intelligence (MMAI) model integrating digitized histopathology and clinical features can identify prostate cancer patients who may benefit from neoadjuvant hormonal therapy (NHT) and whole-pelvic radiotherapy (WPRT). Methods: This secondary analysis of NRG/RTOG 9413 included NHT-treated patients with digitized biopsy slides and clinical data who were not part of the MMAI model optimization. A previously validated MMAI model estimated long-term risk, and Fine-Gray models evaluated interactions between MMAI-derived scores and the radiation field (WPRT vs. prostate-only RT [PORT]) for biochemical failure (BF), chosen over progression-free survival because of extended follow-up and distant metastasis (DM), with subgroup analyses by predefined MMAI strata. Results: Among 81 eligible patients, the MMAI-by-treatment interaction for BF did not confirm a differential effect (p = 0.30). Therefore, subgroup findings should be interpreted as descriptive and hypothesis-generating. Nevertheless, the magnitude effect of WPRT was numerically greater in the MMAI high-risk subgroup (5-yr: 41% vs. 79%; 10-yr: 47% vs. 79%; aHR 0.35 [0.14–0.86]) than in the low–intermediate group (5-yr: 18% vs. 33%; 10-yr: 44% vs. 57%; aHR 0.66 [0.29–1.48]). Conclusions: Although no statistically significant treatment-by-MMAI interaction was demonstrated, these findings are hypothesis-generating and support further investigation of MMAI approaches for guiding WPRT in NRG/RTOG 0534, 0924, GETUG-01, and POP-RT trials.


  • Open Access

    Association Between Regional Cardiac Radiation Dose and Magnetic Resonance Imaging Myocardial Contractility Parameters: A Prospective Pilot Study

    by El-Sayed H. Ibrahim, Slade Klawikowski, Lindsay Puckett, Elizabeth Gore, Dayeong An, Jakub Bychowski, Antonio Sosa, Gerard Walls, Carmen Bergom

    Background/Objectives: Magnetic resonance imaging (MRI) provides a non-invasive means for a comprehensive assessment of the effect of radiation therapy (RT) on heart function. This study aims to determine RT induced cardiotoxicity in thoracic cancer patients using cardiac MRI. Methods: Cardiac MRI was performed at baseline and at six months post-treatment in patients undergoing standard-of-care RT for lung or esophageal cancers at a single institution. Parameters included regional myocardial strain in the longitudinal, circumferential, and radial directions as well as myocardium T1, T2, and extracellular-volume (ECV) maps. Cardiac segmental doses were extracted from the RT planning scans. The relationship between changes in segmental MRI parameters at six months and segmental heart RT dose were investigated. Results: Twelve patients underwent baseline MRI and four completed the follow-up MRI. Five of the segmental strain parameters showed notable changes between baseline and six-month follow-up. Increased doses in the heart base and apex were associated with moderate-to-large and mild deteriorations, respectively, in strain for all regions. Increased doses in the mid-ventricular regions were associated with improved strain in all regions. The segmental analysis revealed that myocardial regions nurtured by the left coronary artery are more negatively affected by radiation compared to those nurtured by the right coronary artery. Conclusions: Alterations in regional tissue and strain parameters on MRI vary according to local myocardial RT dose, suggesting there may be heterogeneity of radiation sensitivity for the heart substructures and regions. Changes in segmental strain parameters may reflect post-RT cardiac remodeling, but larger confirmatory studies are required.

  • Open Access

    Impact of Neoadjuvant Induction Chemotherapy Prior to Chemoradiation on Survival and Surgical Outcomes in Real-World Esophageal Adenocarcinoma Cohort

    by Thomas M. Matoska, Abdullah A. Memon, Lou-Anne Acevedo Moreno, Calista Bulacan, Lisa Rein, Anjishnu Banerjee, Ben George, Lauren Jurkowski, Alexandria Phan, Candice Johnstone, et al.

    Background/objectives: Improvements in esophageal adenocarcinoma (EAC) treatment have reduced mortality. While chemoradiation before surgery was previously a standard of care, updated guidelines recommend peri-operative chemotherapy without chemoradiation. Continued investigation into optimal non-operative treatment paradigms for patients who defer surgery or are not candidates for surgery and certain chemotherapy regimens is needed. The impact of induction chemotherapy prior to chemoradiation on survival and surgical outcomes remains unclear. This study assessed survival and surgical outcomes in a real-world cohort of EAC patients receiving induction chemotherapy before chemoradiation. Methods: This single-institution, IRB-approved, retrospective cohort study included patients with newly diagnosed stage II-IVb (oligometastatic for IVb) EAC who received definitive chemoradiation (radiation ≥ 40 Gy and two cycles of chemotherapy) +/− esophagectomy from 2007 to 2022. Patients receiving induction chemotherapy were compared to those who did not. Endpoints included survival and surgical outcomes. Results: A total of 141 EAC patients received definitive chemoradiation; 83 received induction chemotherapy before chemoradiation. Patients receiving induction chemotherapy were younger (p < 0.01) with slightly lower performance status (p = 0.27) and presented at a more advanced stage (p < 0.001). Median OS was 3.5 years in the induction chemotherapy group compared to 2.2 years (p = 0.10). There was no difference in pathologic complete response (p = 0.81), esophagectomy frequency (p = 0.87), or surgical downstaging between treatment groups (p = 0.84). Conclusions: In this real-world, single-institutional patient cohort investigating induction chemotherapy prior to chemoradiation in EAC, patients receiving induction chemotherapy did well but did not have a statistically significant improvement in survival outcomes or surgical outcomes. This study showed that significant numbers of real-world patients may not receive esophagectomy. Thus, prospective, randomized clinical trials are warranted to better delineate the efficacy and selection of patients for induction chemotherapy when non-operative approaches are favored.

  • Open Access

    Definitive Chemoradiation Associated with Improved Survival Outcomes in Patients with Synchronous Oligometastatic Esophageal Cancer

    by Thomas Matoska, Anjishnu Banerjee, Aditya Shreenivas, Lauren Jurkowski, Monica E. Shukla, Elizabeth M. Gore, Paul Linsky, Mario Gasparri, Ben George, Candice Johnstone, et al.

    Background: The study of oligometastatic esophageal cancer (EC) is relatively new. Preliminary data suggests that more aggressive treatment regimens in select patients may improve survival rates in oligometastatic EC. However, the consensus recommends palliative treatment. We hypothesized that oligometastatic esophageal cancer patients treated with a definitive approach (chemoradiotherapy [CRT]) would have improved overall survival (OS) compared to those treated with a purely palliative intent and historical controls. Methods: Patients diagnosed with synchronous oligometastatic (any histology, ≤5 metastatic foci) esophageal cancer treated in a single academic hospital were retrospectively analyzed and divided into definitive and palliative treatment groups. Definitive CRT was defined as radiation therapy to the primary site with ≥40 Gy and ≥2 cycles of chemotherapy. Results: Of 78 Stage IVB (AJCC 8th ed.) patients, 36 met the pre-specified oligometastatic definition. Of these, 19 received definitive CRT, and 17 received palliative treatment. With a median follow-up of 16.5 months (Range: 2.3–95.0 months), median OS for definitive CRT and palliative groups were 90.2 and 8.1 months (p < 0.01), translating into 5-year OS of 50.5% (95%CI: 32.0–79.8%) vs. 7.5% (95%CI: 1.7–48.9%), respectively. Conclusions: Oligometastatic EC patients treated with definitive CRT benefited from that approach with survival rates (50.5%) that vastly exceeded historical standards of 5% at 5 years for metastatic EC. Oligometastatic EC patients treated with definitive CRT had significantly improved OS compared to those treated with palliative-only intent within our cohort. Notably, definitively treated patients were generally younger and with better performance status versus those palliatively treated. Further prospective evaluation of definitive CRT for oligometastatic EC is warranted.


  • Prophylactic Cranial Irradiation in Non-small Cell Lung Cancer

    by Hina Saeed, Monica E. Shukla, Elizabeth M. Gore

  • Open Access

    Value CMR: Towards a Comprehensive, Rapid, Cost-Effective Cardiovascular Magnetic Resonance Imaging

    by El-Sayed H. Ibrahim, Luba Frank, Dhiraj Baruah, Jason C. Rubenstein, V. Emre Arpinar, Andrew S. Nencka, Kevin M. Koch, L Tugan Muftuler, Orhan Unal, Jadranka Stojanovska, et al.

    CMR is considered the gold standard for measuring heart function, including cardiac volumes and mass. Further, in a single CMR exam, information about cardiac function, structure, tissue composition, and blood flow could be obtained. Nevertheless, CMR is underutilized due to long scanning times, the need for multiple breath-holds, use of a contrast agent, and relatively higher cost compared to echocardiography. In this study, we propose a rapid CMR exam based on recent developments in imaging sequences. The proposed exam is both rapid and provides comprehensive cardiovascular information without the need for a contrast agent or multiple breath-holds. The developed exam includes advanced sequences for evaluating global and regional cardiac functions, myocardial tissue characterization, and flow hemodynamics in the heart, valves, and large vessels. Time-consuming conventional sequences have been replaced by advanced sequences, which resulted in reducing scan time from > 1 hour with conventional CMR exam to <20 minutes with the proposed rapid CMR exam. Specifically, conventional two-dimensional (2D) cine and phase-contrast (PC) sequences have been replaced by optimized three-dimensional (3D)-cine and four-dimensional (4D)-flow sequences, respectively. Compared to 2D cine imaging that requires 12-16 separate breath-holds, the implemented 3D-cine sequence allows for whole heart coverage in 1-2 breath-holds; thus, reducing scan time by 80-90%. Similarly, compared to 2D PC flow imaging that requires multiple breath-holds and the presence of an experienced cardiac operator for precise prescription of the imaging planes, the implemented 4D-flow sequence allows for whole-chest coverage in ∼10-minute, free-breathing acquisition without the need for a navigator echo, which makes scan time independent of the patient’s breathing pattern. Furthermore, conventional myocardial tagging has been replaced by the fast strain-encoding (SENC) sequence, which reduces scan time from one slice per breath-hold to only one slice per heartbeat (∼1 second). Finally, T1 and T2 mapping sequences are included in this proposed exam, which allow for myocardial tissue characterization without the need for contrast. The proposed rapid exam has been tested on volunteers and measurements showed good agreement with those from conventional sequences despite the significant reduction in scan time. In conclusion, we propose a rapid, contrast-free, and comprehensive cardiovascular exam that does not require repeated breath-holds or a cardiac experienced operator to run the exam, which would result in improving cost effectiveness of CMR and increasing its adoption in clinical practice.


  • Optimized cardiac functional MRI of small-animal models of cancer radiation therapy

    by El-Sayed H. Ibrahim, Dhiraj Baruah, Matthew Budde, Jason Rubenstein, Anne Frei, Rachel Schlaak, Elizabeth Gore, Carmen Bergom


  • Dosimetric Predictors of Cardiotoxicity in Thoracic Radiotherapy for Lung Cancer

    by Jenna F. Borkenhagen, Carmen Bergom, Cooper T. Rapp, Slade J. Klawikowski, Lisa E. Rein, Elizabeth M. Gore


  • Randomized Phase II Study Comparing Prophylactic Cranial Irradiation Alone to Prophylactic Cranial Irradiation and Consolidative Extracranial Irradiation for Extensive-Disease Small Cell Lung Cancer (ED SCLC): NRG Oncology RTOG 0937

    by Elizabeth M. Gore, Chen Hu, Alexander Y. Sun, Daniel F. Grimm, Suresh S. Ramalingam, Neal E. Dunlap, Kristin A. Higgins, Maria Werner-Wasik, Aaron M. Allen, Puneeth Iyengar, et al.


  • Randomized phase II study of preoperative chemoradiotherapy (CRT)+/- Panitumumab (P) followed by consolidation chemotherapy (C) in potentially operable locally advanced (stage IIIa, N2+) non-small cell lung cancer (LANSCLC): Nrg oncology/RTOG 0839.

    by Martin J. Edelman, Chen Hu, Quynh-Thu Le, Jessica Donington, Warren D. D'Souza, Adam Dicker, Billy W. Loo, Elizabeth Gore, Gregory M.M. Videtic, Nathaniel R. Evans, et al.

    8510 Background: Multimodality therapy has curative potential in LANSCLC. Mediastinal nodal sterilization (MNS) after induction CRT can serve as an intermediate marker for efficacy. RTOG 0229 demonstrated the feasibility and efficacy of combining full dose XRT (61.2GY) with C followed by resection and C. Based upon that experience and evidence that EGFR antibodies are radiosensitizing, we explored adding P to CRT followed by resection and C in LANSCLC with a primary endpoint of MNS. Methods: Resectable LANSCLC pts were eligible if deemed suitable for trimodality therapy prior to treatment. Surgeons were required to demonstrate expertise after CRT and adhere to specific management guidelines. Induction C consisted of weekly CBDCA (AUC = 2.0) and paclitaxel (50 mg/m2). Concurrent RT: 60 Gy delivered in 30 2.0 Gy fractions. There was a 2:1 randomization in favor of P at 2.5 mg/kg weekly x 6. Mediastinum was pathologically reassessed prior to or at the time of resection. Consolidation C was CBDCA AUC = 6, paclitaxel 200 mg/m2q 21d x 2. The study was designed to detect an improvement in MNS from 52% to 72%. Using a 0.15 1-sided type 1 error and 80% power, 97 patients were needed. Results: The study was opened 11/2010 and closed 8/2015 by the Data Monitoring Committee after 71 pts were accrued for futility and excessive toxicity in the P arm. 61 pts were eligible. Demographics (see table). 19 pts (86%) on CRT and 30 pts (77%) on CRT +P underwent surgery. Toxicity: 3 (13.6%) grade 4 AEs and 0 (0%) grade 5 AEs on CRT vs. 6 (15.4%) grade 4 AEs and 3 (7.7%) grade 5 AEs on CRT+P (all postoperative). MNS rates were 68.2% (95% CI 45.1%, 86.1%) and 48.7% (95% CI 32.4%, 65.2%), for CRT and CRT +P, respectively (p = .96). Conclusions: The addition of P to CRT did not improve MNS. There was an unexpectedly high mortality rate on the P arm, though the relationship to P is unclear. The control arm had outcomes similar to RTOG 0229. Clinical trial information: NCT00979212.